Ibio Inc is a biotechnology company that focuses on the development and commercialization of innovative biologic therapies for various diseases. Utilizing its proprietary plant-based expression platform, the company aims to create a range of scalable, cost-effective solutions for producing proteins and antibodies that can be used in therapies and vaccines. Ibio also engages in collaborations and partnerships to accelerate the development of its product pipeline and enhance its technology, ultimately striving to improve patient outcomes in areas such as infectious diseases and cancer. Read More
Wondering how the US markets performed in the middle of the day on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis.
SurgePays, Inc. (NASDAQ: SURG), a rapidly expanding technology and telecommunications company serving the prepaid and underserved consumer markets, released an update highlighting its multi-vertical growth strategy designed to scale revenue across wireless, fintech, and retail partner ecosystems. The company confirmed that Lifeline Wireless remains the fastest path to near-term profitability, while its prepaid brand LinkUp Mobile, HERO MVNE services , prepaid fintech top-up platform , and ClearLine SaaS retail media network form the backbone of its 2026 and long-term expansion plans.
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Specificity, Inc. (OTCQB: SPTY), a fast-scaling ad tech disruptor redefining digital marketing precision, has seen its stock skyrocket 933% this week, rallying from an intraday low of $0.15 on October 16 to an intraday high of $1.40 on October 22 , as Wall Street responds enthusiastically to the company’s new executive appointments and aggressive growth trajectory.
Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
